AUTHORS
Abiola Bolarinwa, MBBS, MSc, FMCPath, Saubia Fathima, MD2, Aref Al-Kali, M.D.3, Hassan B Alkhateeb, M.D.4, Abhishek Avinash Mangaonkar, MBBS5, Antoine N. Saliba, M.D.6, Mehrdad Hefazi Torghabeh, MD7, Aasiya Matin, MBBS8, James Foran, FRCPC9, Jeanne Palmer, MD10, Talha Badar, MD11, Cecilia Arana Yi, M.D.12, Michelle Elliott, MD13, Mark R. Litzow, MD14, William Hogan, M.B., B.Ch.15, Mithun Shah, MD, PhD16, Mrinal M. Patnaik, MD, MBBS17, Animesh Pardanani, PhD, MBBS18, Kaaren Reichard, MD19, Cinthya J Zepeda Mendoza20, Rong He, MD21, Kebede Begna, M.D.22, Naseema Gangat, MBBS23, Ayalew Tefferi, MD24
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Jacksonville, Florida, United States
10 Mayo Clinic, Scottsdale, Arizona, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 Mayo Clinic, Scottsdale, Arizona, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
Real-world data to inform the optimal choice of frontline treatment regimen in newly diagnosed acute myeloid leukemia (ND-AML) within distinct clinical contexts remain sparse. In this retrospective study, we evaluated overall and context-stratified treatment response and survival following 7+3, CPX-351, or Ven-HMA induction in ELN-2022 adverse (adv)/intermediate (int) risk ND-AML.
Methods:
Formal criteria were used for AML diagnosis and sub-classification, risk stratification, and adjudication of response (Blood 2022;140:1345). Patients with ELN-2022 favorable risk AML were excluded. Complete remission, with or without count recovery (CR/CRi), allogeneic stem cell transplantation (ASCT)-censored overall survival (OS), and post-transplant survival (PT-OS) were calculated. Treatment comparisons were adjusted in multivariable analyses (MVA) for independent predictors of outcome within each clinical context.
Results:
874 patients with adv/int-risk AML were selected from a larger database (N=1,147) of Mayo Clinic patients with ND-AML. Frontline therapy included 7+3 (n=362; median age 58 years), CPX-351 (n=101; 65 years), or Ven-HMA (n=411; 73 years; p<0.01). Corresponding CR/CRi rates were 69%, 55%, and 56% (p<0.01); the difference lost significance (p=0.9) during MVA.
At median follow-up of 54 months (mos), 561 (64%) deaths, 289 (33%) relapses, and 383 (44%) ASCTs were documented. Median OS was 29, 12, and 11 mos for 7+3, CPX-351, and Ven-HMA, respectively (p<0.01), with the superiority of 7+3 and similarity between CPX-351 and Ven-HMA remaining intact (p<0.01) in MVA that included other independent predictors of inferior OS: male sex, secondary vs primary/therapy-related AML, adverse karyotype (AK), EZH2MUT, IDH2WT, PTPN11MUT, TET2MUT, and TP53MUT (p<0.01). PT-OS was adversely impacted by AK (p=0.01), TP53MUT (p<0.01), SF3B1MUT (p<0.01), and JAK2MUT (p=0.03), but not by regimen (p=0.6).
Analysis stratified by ELN-2022 genetic risk
CR/CRi rates in patients with int-risk AML (n=162) were 77%, 74% and 71% for 7+3, CPX-351 and Ven-HMA, respectively (p=0.8); non-significance was confirmed by MVA. The corresponding median OS was 36, 13, and 29 mos (p=0.03); CPX-351 was associated with inferior OS, compared with both 7+3 (p<0.01) and Ven-HMA (p=0.03) while the latter two displayed similar OS, confirmed by MVA. CR/CRi rates in adv-risk AML (n=625) were 61%, 51%, 52% for 7+3, CPX-351 and Ven-HMA, respectively (p=0.1). Non-significance persisted during MVA. The corresponding median OS was 20, 10 and 9 mos (p<0.01). In MVA, OS advantage associated with 7+3 remained significant when compared to Ven-HMA (p=0.01), but not with CPX-351 (p = 0.2). OS was similar between CPX-351 and Ven-HMA (p = 0.4).
Analysis stratified by AML subtype
In primary AML (N=532), CR/CRi rates were 71%, 50% and 62% for 7+3 (n=302), CPX-351 (n=36) and Ven-HMA (n=194), respectively (p=0.01); significance was lost during MVA (p=0.2). The corresponding median OS was 39, 14, and 13 mos (p<0.01) with the difference confirmed by MVA for 7+3 vs. Ven-HMA (p<0.01). In secondary AML (N=229) CR/CRi rates were 48%, 50% and 41% for 7+3 (n=40), CPX-351 (n=46) and Ven-HMA (n=143), respectively (p=0.5) with non-significance confirmed by MVA. The corresponding median OS was 8, 8, and 9 mos (p=0.8) with non-significance confirmed by MVA (p=0.6). In therapy-related AML, CR/CRi rates were 75%, 79% and 68% for 7+3 (n=20), CPX-351 (n=19) and Ven-HMA (n=74), respectively (p=0.6), with non-significance confirmed by MVA. The corresponding median OS was 13, 21, and 11 mos (p=0.05) with borderline significance lost during MVA (p=0.6).
Analysis restricted to AML-MR-G/C (N=403)
CR/CRi rates were 65%, 63%, and 61% for 7+3 (n=147), CPX-351 (n=56) and Ven-HMA (n=200), respectively (p=0.7) and remained not significant during MVA. The corresponding median OS was 29, 12, and 15 mos (p<0.01); in MVA, 7+3 showed a trend towards superior OS, compared to Ven-HMA (p=0.05). Specifically, comparisons of CPX-351 to 7+3 (p=0.3) and Ven-HMA (p=0.6) were not significant. Results were similar when the analysis was limited to the cohort with AML-MR gene mutations only.
Conclusion: The current study does not suggest superiority of CPX-351 over either 7+3 or Ven-HMA in adv-/int-risk AML, in any context, including in AML-MRG, AML-MRG/C, or therapy-related AML. Overall outcome was affected more by AML subtype and adverse karyotype. Salient differences favoring 7+3 require confirmation by additional studies.
DISCLOSURES
Abiola Bolarinwa, MBBS, MSc, FMCPath: No relevant conflicts of interest to declare.